At a glance
- Current status: Closed
- Fund type: EIS Knowledge Intensive
Investment goal: Capital growth
- Focus: Life sciences
- Target returns: 30% IRR
Target holding period: 7 years
- Minimum subscription: £25,000
The objective of the Fund is to invest in a balanced portfolio of early-stage life science businesses with the aim of generating an excellent return for Investors. By doing this we will help to create and grow some exciting, innovative and potentially life changing companies. The businesses the Fund will invest in may have an impact on their local economy, providing highly skilled jobs and further increasing the overall strength of the UK life sciences sector.
Investment selection process
A team of venture builders and WAPG’s network of science infrastructure across the UK provide privileged access to a stream of validated investment opportunities. Our sites and venture development activity act as funnels, drawing in the best opportunities in the area.
WAPG will be working with opportunities from various sources including ICURe, Oxford and East Midlands AHSN Accelerators, Scottish University Accelerator, Scottish Universities Accelerator, Scottish High Growth Programme, Pharma Partners, WAPG's own network.
EIS tax incentives
The companies the fund invest in are expected to be EIS & Knowledge Intensive (KI)-qualifying, which makesPioneer Life Sciences Knowledge Intensive EIS Fund EIS-KI suitable for qualifying clients who would potentially benefit from the following tax reliefs:
- Up to 30% income tax relief (As the fund is knowledge-intensive you can choose to carry back income tax relief to the previous tax year or in the tax year that the Fund closes)
- Tax-free investment growth
- Capital gains deferral
- Inheritance tax relief
- Loss relief
Please note: EIS tax reliefs are only made available to investors because of the higher risks associated with investing in early-stage companies. Also, the availability of tax reliefs will depend on the investor's personal circumstances, and tax legislation can change in the future.
Example of fund team's previous investments
Founded in 2016, and derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies.
.webp){kind=small}
Based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK due diligence and modelling and simulation, and has worked directly on the predictions of human PK and dose for eight compounds that have entered clinics.
Roylance Pharma is a provider of biobanking and stability storage facilities to store pharmaceutical and biological samples.
.svg)